<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 1pt; margin-bottom: 1pt"><DIV STYLE="font-size: 1pt; border-top: Black 3.5pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Washington D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PURSUANT TO SECTION 13 OR 15(d) OF</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>THE SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Date of Report (Date of earliest event reported):
February 29, 2012</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>GENESIS BIOPHARMA, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Name of small business issuer specified in
its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR>
    <TD STYLE="width: 32%; vertical-align: top; font-weight: bold; text-align: center">Nevada</TD>
    <TD STYLE="width: 2%; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="width: 32%; vertical-align: top; font-weight: bold; text-align: center">000-53127</TD>
    <TD STYLE="width: 2%; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="width: 32%; vertical-align: top; font-weight: bold; text-align: center">75-3254381</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center">(State or other jurisdiction</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">(Commission File No.)</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">(I.R.S. Employer</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center">of incorporation)</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">Identification No.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>11500 Olympic Blvd., Suite 400<BR>
Los Angeles, CA 90064</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Address of principal executive offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Not Applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">(former name or former address,
if changed since last report)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(866) 963-2220</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Registrant&rsquo;s telephone number)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD>Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD>Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD>Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD>Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</TD></TR></TABLE>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 1pt; margin-bottom: 1pt"><DIV STYLE="font-size: 1pt; border-top: Black 4.5pt solid; border-bottom: Black 0 solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo --><!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"><B>Item 1.01 &#9;Entry into a Material Definitive Agreement.
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Effective July 27, 2011, Genesis Biopharma, Inc., a Nevada corporation,
completed an offering of an aggregate $5,000,000 of its seven (7%) percent Tranche A Senior Unsecured Convertible Notes and Tranche
B Senior Unsecured Convertible Notes (collectively, the &ldquo;Notes&rdquo;) and five (5) year common stock purchase warrants (Tranche
A Warrants and Tranche B Warrants), having an initial exercise price of $1.25 (the &ldquo;Note Warrants&rdquo;), which was subject
to anti-dilution adjustments for issuances below the exercise price then in effect and customary adjustments in the event of stock
split, reverse stock split, stock dividend, recapitalization, reorganization or similar transaction involving this company&rsquo;s
common stock. Both the Notes and the Note Warrants have previously been amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The Notes initially were to mature November 30, 2011. The Notes
have been amended five prior times to extend the maturity date of the Notes, most recently to February 29, 2012. Effective February
29, 2012, we entered into Amendment No. 6 to Tranche A Senior Unsecured Convertible Notes and Tranche B Senior Unsecured Convertible
Notes (the &ldquo;Amendment&rdquo;) with the holders of the Notes to further extend the maturity date. Under the Amendment, the
definition of the term &ldquo;Maturity Date&rdquo; was amended to be March 13, 2012. In addition, the Amendment also contained
provisions that changed the conversion price of the Notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The Notes initially were convertible into shares of our common stock
at an initial &ldquo;Conversion Price&rdquo; of $1.25, which Conversion Price initially was adjustable (in addition to anti-dilution
adjustments for issuances below the conversion price then in effect and customary adjustments in the event of stock split, reverse
stock split, stock dividend, recapitalization, reorganization or similar transaction involving this company&rsquo;s common stock)
if at any time after the date of issuance we completed an equity financing for gross proceeds of at least $10,000,000 (a &ldquo;Qualified
Offering&rdquo;). Under the provisions of the Notes, for issuances of common stock or common stock equivalents at a purchase price
less than the Conversion Price then in effect, subject to certain exceptions, the Conversion Price will be reduced to the purchase
price in such subsequent offering. However, in the event of a Qualified Offering, the Notes initially provided that the Conversion
Price would be adjusted to the lesser of (i) $1.25 and (ii) eighty-five percent (85%) of the purchase price paid by investors in
the subsequent equity financing. <B> </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The amendments to the Notes, including the Amendment, modified
the forgoing definition of the &ldquo;Conversion Price&rdquo; of the Notes. The Amendment (and prior Amendment No. 4 to
Notes, entered into effective as of January 13, 2012), now provides that the &ldquo;Conversion Price&rdquo; will be adjusted
if at any time after the issuance date of the Notes, we consummate one or more equity financings (each, a &ldquo;Qualified
Offering&rdquo;), or if we issue securities to any consultants, officers, directors, employees or third parties (&ldquo;Other
Parties&rdquo;), for a price per share that is below the fair market value of the Common Stock as measured by the closing
sale price on the date of each such issuance, the Conversion Price shall be adjusted to the lesser of (i) $1.25 and (ii)
seventy-five percent (75%) of the purchase price per share of Common Stock payable by the investors in each such subsequent
equity financing or by such Other Parties. In case any rights, warrants or options to subscribe for or purchase shares of
common stock or convertible securities are  sold with shares of Common Stock in one integrated transaction, the value
assigned to any such option, warrant, etc. (the &ldquo;<B>Option Value</B>&rdquo;) shall be calculated using
the Black-Scholes model using a &ldquo;volatility&rdquo; of 100 and a &ldquo;risk free rate&rdquo; of 2.3% and, for purposes
of determining the Conversion Price, the purchase price per share of Common Stock shall equal the amount paid per share
of Common Stock in the Qualified Offering minus the Option Value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The Note Warrants were previously also amended in connection
with the amendment of the Notes to amend the definition of the &ldquo;Exercise Price&rdquo; at which the Note Warrants could
be exercised. Amendment No. 4 to Note Warrants entered into effective as of January 31, 2012 provides that, in addition to
adjustments for issuances below the exercise price then in effect and customary adjustments in the event of a stock split,
reverse stock split, stock dividend, recapitalization, reorganization or similar transaction involving this company&rsquo;s
common stock, if at any time after the date of issuance we consummate a Qualified Offering (defined as any equity financing),
or if we issue shares to Other Parties, for a price per share that is below the closing sale price of our stock on the date
of issuance, the &ldquo;Exercise Price&rdquo; of the Note Warrants shall be adjusted to the lesser of (i) $1.25 and (ii) 75%
of the purchase price per share of Common Stock payable by the investors in such Qualified Offering or by such Other Parties.
Until July 27, 2013, under the anti-dilution provisions of the Note Warrants, for issuances, or deemed issuances of shares
(other than issuances in a Qualified Offering) at a purchase price less than the Exercise Price then in effect the Exercise
Price will be reduced to the purchase price in such subsequent offering. In case any Option is issued in connection with the
sale of Common Stock in a Qualified Offering, the Option Value shall be calculated using the Black-Scholes model using a
&ldquo;volatility&rdquo; of 100 and a &ldquo;risk free rate&rdquo; of 2.3% and, for purposes of determining the Exercise
Price, the purchase price per share of Common Stock shall equal the amount paid per share of Common Stock in the Qualified
Offering minus the Option Value. Upon each such adjustment of the Exercise Price hereunder, the number of shares issuable
under each Note Warrant shall be adjusted to the number of shares of Common Stock determined by multiplying the Exercise
Price in effect immediately prior to such adjustment by the number of shares acquirable upon exercise of the Note
Warrant immediately prior to such adjustment and dividing the product thereof by the Exercise Price resulting from such
adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">A copy of Amendment No. 6 to the Notes and Amendment No. 4 the Note
Warrants is attached as Exhibit 10.1 and 10.2 hereto, respectively, and the foregoing summary of those amendments is qualified
by reference to such exhibits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Certain of the outstanding warrants that we issued in 2010 and 2011
contain re-set provisions that state that, if the conversion price or exercise price of our convertible securities, options or
warrants is lowered to a price below the exercise price of the 2010 and 2011 warrants, then the exercise price of the 2010 and
2011 warrants will be reduced to the new, lower price of the other convertible securities, options or warrants. Accordingly, in
the event that Conversion Price of the Notes is reduced and the Exercise Price of the Note Warrants is reduced to a price below
the current exercise price of the 2010 and 2011 warrants, then the exercise price of those warrants will also be reduced (and the
number of shares that can be purchased under those warrants will increase).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"><B>Item 9.01. Financial Statements and Exhibits</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">(d)&#9;<U>Exhibits</U>. The following
exhibit is included as part of this report.</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 12%">10.1</TD>
    <TD STYLE="width: 88%">Form of Amendment No. 6 to Tranche A Senior Unsecured Convertible Notes and Tranche B Senior Unsecured Convertible Notes, effective as of February 29, 2012</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>10.2</TD>
    <TD>Form of Amendment No. 4 Tranche A Warrants to Purchase Common Stock and Tranche B Warrants to Purchase Common Stock</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">SIGNATURES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">Pursuant to the
requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the
undersigned hereunto duly authorized.</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 53%; padding: 0; text-indent: 0">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Date:&#9;March 6, 2012</P></TD>
    <TD STYLE="width: 45%; padding: 0; text-indent: 0">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">GENESIS BIOPHARMA, INC.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 22.3pt; text-indent: -22.3pt">By:&#9;<U>/s/ ANTHONY CATALDO&#9;<BR>
        </U>Anthony Cataldo, Chief Executive Officer</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0in">&nbsp;</P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="margin: 0"></P>

</BODY>
</HTML>
[{"type": "8-K", "sequence": "1", "filename": "v304930_8k.htm", "description": "FORM 8-K", "secsgml_size_bytes": 20493}]
{"company-data": {"conformed-name": "Genesis Biopharma, Inc", "cik": "0001425205", "assigned-sic": "4731", "irs-number": "753254381", "state-of-incorporation": "NV", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-53127", "film-number": "12671573"}, "business-address": {"street1": "1601 N. SEPULVEDA BLVD., #632", "city": "MANHATTAN BEACH", "state": "CA", "zip": "90266", "phone": "866-963-2220"}, "mail-address": {"street1": "1601 N. SEPULVEDA BLVD., #632", "city": "MANHATTAN BEACH", "state": "CA", "zip": "90266"}, "former-company": {"former-conformed-name": "FREIGHT MANAGEMENT CORP", "date-changed": "20080128"}}
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
February 29, 2012
GENESIS BIOPHARMA, INC.
(Name of small business issuer specified in
its charter)
Nevada
000-53127
75-3254381
(State or other jurisdiction
(Commission File No.)
(I.R.S. Employer
of incorporation)
Identification No.)
11500 Olympic Blvd., Suite 400
Los Angeles, CA 90064
(Address of principal executive offices)
Not Applicable.
(former name or former address,
if changed since last report)
(866) 963-2220
(Registrant's telephone number)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 1.01 	Entry into a Material Definitive Agreement.
Effective July 27, 2011, Genesis Biopharma, Inc., a Nevada corporation,
completed an offering of an aggregate $5,000,000 of its seven (7%) percent Tranche A Senior Unsecured Convertible Notes and Tranche
B Senior Unsecured Convertible Notes (collectively, the "Notes") and five (5) year common stock purchase warrants (Tranche
A Warrants and Tranche B Warrants), having an initial exercise price of $1.25 (the "Note Warrants"), which was subject
to anti-dilution adjustments for issuances below the exercise price then in effect and customary adjustments in the event of stock
split, reverse stock split, stock dividend, recapitalization, reorganization or similar transaction involving this company's
common stock. Both the Notes and the Note Warrants have previously been amended.
The Notes initially were to mature November 30, 2011. The Notes
have been amended five prior times to extend the maturity date of the Notes, most recently to February 29, 2012. Effective February
29, 2012, we entered into Amendment No. 6 to Tranche A Senior Unsecured Convertible Notes and Tranche B Senior Unsecured Convertible
Notes (the "Amendment") with the holders of the Notes to further extend the maturity date. Under the Amendment, the
definition of the term "Maturity Date" was amended to be March 13, 2012. In addition, the Amendment also contained
provisions that changed the conversion price of the Notes.
The Notes initially were convertible into shares of our common stock
at an initial "Conversion Price" of $1.25, which Conversion Price initially was adjustable (in addition to anti-dilution
adjustments for issuances below the conversion price then in effect and customary adjustments in the event of stock split, reverse
stock split, stock dividend, recapitalization, reorganization or similar transaction involving this company's common stock)
if at any time after the date of issuance we completed an equity financing for gross proceeds of at least $10,000,000 (a "Qualified
Offering"). Under the provisions of the Notes, for issuances of common stock or common stock equivalents at a purchase price
less than the Conversion Price then in effect, subject to certain exceptions, the Conversion Price will be reduced to the purchase
price in such subsequent offering. However, in the event of a Qualified Offering, the Notes initially provided that the Conversion
Price would be adjusted to the lesser of (i) $1.25 and (ii) eighty-five percent (85%) of the purchase price paid by investors in
the subsequent equity financing.
The amendments to the Notes, including the Amendment, modified
the forgoing definition of the "Conversion Price" of the Notes. The Amendment (and prior Amendment No. 4 to
Notes, entered into effective as of January 13, 2012), now provides that the "Conversion Price" will be adjusted
if at any time after the issuance date of the Notes, we consummate one or more equity financings (each, a "Qualified
Offering"), or if we issue securities to any consultants, officers, directors, employees or third parties ("Other
Parties"), for a price per share that is below the fair market value of the Common Stock as measured by the closing
sale price on the date of each such issuance, the Conversion Price shall be adjusted to the lesser of (i) $1.25 and (ii)
seventy-five percent (75%) of the purchase price per share of Common Stock payable by the investors in each such subsequent
equity financing or by such Other Parties. In case any rights, warrants or options to subscribe for or purchase shares of
common stock or convertible securities are  sold with shares of Common Stock in one integrated transaction, the value
assigned to any such option, warrant, etc. (the "
Option Value
") shall be calculated using
the Black-Scholes model using a "volatility" of 100 and a "risk free rate" of 2.3% and, for purposes
of determining the Conversion Price, the purchase price per share of Common Stock shall equal the amount paid per share
of Common Stock in the Qualified Offering minus the Option Value.
2
The Note Warrants were previously also amended in connection
with the amendment of the Notes to amend the definition of the "Exercise Price" at which the Note Warrants could
be exercised. Amendment No. 4 to Note Warrants entered into effective as of January 31, 2012 provides that, in addition to
adjustments for issuances below the exercise price then in effect and customary adjustments in the event of a stock split,
reverse stock split, stock dividend, recapitalization, reorganization or similar transaction involving this company's
common stock, if at any time after the date of issuance we consummate a Qualified Offering (defined as any equity financing),
or if we issue shares to Other Parties, for a price per share that is below the closing sale price of our stock on the date
of issuance, the "Exercise Price" of the Note Warrants shall be adjusted to the lesser of (i) $1.25 and (ii) 75%
of the purchase price per share of Common Stock payable by the investors in such Qualified Offering or by such Other Parties.
Until July 27, 2013, under the anti-dilution provisions of the Note Warrants, for issuances, or deemed issuances of shares
(other than issuances in a Qualified Offering) at a purchase price less than the Exercise Price then in effect the Exercise
Price will be reduced to the purchase price in such subsequent offering. In case any Option is issued in connection with the
sale of Common Stock in a Qualified Offering, the Option Value shall be calculated using the Black-Scholes model using a
"volatility" of 100 and a "risk free rate" of 2.3% and, for purposes of determining the Exercise
Price, the purchase price per share of Common Stock shall equal the amount paid per share of Common Stock in the Qualified
Offering minus the Option Value. Upon each such adjustment of the Exercise Price hereunder, the number of shares issuable
under each Note Warrant shall be adjusted to the number of shares of Common Stock determined by multiplying the Exercise
Price in effect immediately prior to such adjustment by the number of shares acquirable upon exercise of the Note
Warrant immediately prior to such adjustment and dividing the product thereof by the Exercise Price resulting from such
adjustment.
A copy of Amendment No. 6 to the Notes and Amendment No. 4 the Note
Warrants is attached as Exhibit 10.1 and 10.2 hereto, respectively, and the foregoing summary of those amendments is qualified
by reference to such exhibits.
Certain of the outstanding warrants that we issued in 2010 and 2011
contain re-set provisions that state that, if the conversion price or exercise price of our convertible securities, options or
warrants is lowered to a price below the exercise price of the 2010 and 2011 warrants, then the exercise price of the 2010 and
2011 warrants will be reduced to the new, lower price of the other convertible securities, options or warrants. Accordingly, in
the event that Conversion Price of the Notes is reduced and the Exercise Price of the Note Warrants is reduced to a price below
the current exercise price of the 2010 and 2011 warrants, then the exercise price of those warrants will also be reduced (and the
number of shares that can be purchased under those warrants will increase).
Item 9.01. Financial Statements and Exhibits
(d)
Exhibits
. The following
exhibit is included as part of this report.
10.1
Form of Amendment No. 6 to Tranche A Senior Unsecured Convertible Notes and Tranche B Senior Unsecured Convertible Notes, effective as of February 29, 2012
10.2
Form of Amendment No. 4 Tranche A Warrants to Purchase Common Stock and Tranche B Warrants to Purchase Common Stock
3
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the
undersigned hereunto duly authorized.
Date:	March 6, 2012
GENESIS BIOPHARMA, INC.
By:
/s/ ANTHONY CATALDO
Anthony Cataldo, Chief Executive Officer
4